February 19th, 2015
Companies Plan To Resume Renal Denervation Trials
Larry Husten, PHD
Medtronic and Boston Scientific have announced plans to start phase 2 clinical trials this year for their updated renal denervation catheters. The once promising new technology is intended to treat hypertension unresponsive to drug therapy. The failure last year of Medtronic’s Symplicity HTN-3, the first large pivotal trial to rigorously test renal denervation, sent manufacturers back to their drawing boards to redesign the devices.
Earlier this week Medtronic disclosed in its quarterly report that it planned to soon submit to the FDA its application for an investigational device exemption (IDE) for its next-generation renal denervation device. The spiral-shaped device has multiple electrodes and is designed to achieve more comprehensive ablation of the renal arteries. The company is seeking FDA approval to proceed with a phase II trial.
In its quarterly report Boston Scientific said it plans to begin enrolling patients in the first half of this year in a phase II trial, called REDUCE-HTN REINFORCE, testing its Vessix platform. The company has not yet released details of the protocol but said the FDA has approved the protocol.
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension